Notice of Results
CelLBxHealth plc
("CelLBxHealth" or "the Company")
Notice of Results and Investor Presentation
Guildford, UK and Plymouth Meeting, U.S. - 16 June 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, will announce its preliminary results for the year ended 31 December 2025 on Monday, 22 June 2026.
Online investor presentation
Peter Collins, Chief Executive Officer, will provide an overview of the Company's preliminary results via the Investor Meet Company platform at 11:00 BST on Monday, 22 June 2026. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 09:00 BST the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet CelLBxHealth plc via: https://www.investormeetcompany.com/cellbxhealth-plc/register
Investors who already follow CelLBxHealth plc on the Investor Meet Company platform will automatically be invited.
For further information:
CelLBxHealth plc
Peter Collins, Chief Executive Officer
Jan Groen, Executive Chairman
via Walbrook PR
Cavendish (NOMAD and Broker)
Geoff Nash / Isaac Hooper (Corporate Finance)
Sunila de Silva (Corporate Broking)
Nigel Birks (Life Science Specialist Sales)
+44 (0)20 7220 0500
Walbrook PR (Investor and Media Relations)
Paul McManus / Alice Woodings
Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
About CelLBxHealth plc
CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.
Commercial focus span three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through a combination of strategic partnerships and in-house development.
For more information, visit https://cellbxhealth.com/.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDNORSFEFMIEMSESM
